Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Probing DC-SIGN-glycan multivalent interaction and dendritic cell immune regulation using polyvalent multifunctional glycan-gold nanoparticles (Glycan-PMN)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-02-01
End date: 2023-08-31
Duration (months): 24.0
Total project cost (EUR): 224933.76
EU funding (EUR): 224933.76
Participants: 1
Project status: CLOSED

Multivalent lectin-glycan interactions is central to pathogen infection and immune response regulation. Dendritic cell (DC) surface tetrameric lectin, DC-SIGN, is particularly important in discriminating self- and foreign (pathogen) glycan patterns and regulates DC immune response. The underlying structural and immune regulation mechanisms remain poorly understood. As various lectins have overlapping glycan specificity, this greatly limits our ability to design glycoconjugates that can specifically target DC-SIGN to block infection or exploit its powerful immune regulation to develop effective immunotherapies. Here we will address this challenge by developing polyvalent glycan-gold nanoparticles (GNPs) & multiple GNP assemblies to enhance binding affinity and specificity by exploiting multivalency. By tuning GNP surface glycan structure, valency, inter-glycan spacing, size and shape and study their binding with DC-SIGN/R, we will reveal the optimal glycan structure for DC-SIGN binding. By exploiting GNP’s fluorescence quenching, we will develop a new lectin-glycan affinity quantifying method. We will use glycan-GNPs to block pseudo-Ebola virus infection of DC-SIGN expressing cells and correlate the affinity and inhibition potency. We will study how glycan-GNP binding controls DC surface DC-SIGN clustering, binding to intracellular proteins & regulating cytokine production to reveal the . This research is extremely timely & important because it will, 1) establish a design rule for potent, highly specific DC-SIGN targeting; 2) develop a new lectin-glycan affinity quantification method; 3) reveal correlation between DC-SIGN/R binding affinity & viral inhibition potency; 4) elucidate how DC-SIGN-glycan binding signal is transduced to regulate DC immune function, paving way to develop effective immunotherapies against deadly immune-dysregulation diseases (e.g. cancer, allergy, & auto-immune diseases) by exploiting DC-SIGN’s powerful immune regulation function.

Keywords: glycan nanoparticle,multivalent protein sugar interaction,binding affinity,viral inhibition,immune regulation,dc sign,dendritic cell,cellular assay,biophysics,structural mechanism,cancer
TrojanDC (TrojanDC)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Sweden
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-12-01
End date: 2020-05-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Asgard Therapeutics, a Swedish start-up company, was founded based on a unique proprietary in vivo cell reprogramming technology. This paradigm-shifting gene therapy has the unique potential to overhaul the cancer immunotherapy market. Our gene therapy, named TrojanDC, delivers immune-genes into the tumor and re-educates cancer cells to become anti-tumor immune cells. It uses a viral vector to deliver a unique combination of three critical transcription factors (genes) through intra-tumoral injection. The transcription factors make cancer cells become antigen-presenting dendritic cells. These immunogenic cells present their own diversity of tumor-specific antigens to effector immune cells, reliably and robustly inducing immune responses that eradicate the heterogeneous tumor. Cancer remains a major health challenge. Currently available immunotherapies show strong effectiveness only in a limited number of patients, and often lose their efficacy as the tumor develops resistance. In addition, immunotherapies come with high price (e.g. CAR-T cell approach costing approx. € 350k/patient). Despite these shortcomings, the global immune-oncology market is one of the fastest growing therapeutics markets (€114.6 B by 2024 with a CAGR of 14.3%). Large players like BMS, Merck and Roche have shown to be keen on acquisitions of high-potential technologies. There is thus an urgent need and high demand for innovative cost-effective immunotherapies consistently effective in a broader range of cancer patients – something that Asgard Therapeutics will deliver with TrojanDC in the form of a personalized and highly specific immune therapy using a ‘one-size-fits-all’ approach. With in-vivo proof-of-concept data already obtained and a balanced team of high-performing scientists and seasoned entrepreneurs, Asgard Therapeutics has locked up key factors towards maximizing its chances of success. This SME instrument grant will ensure a sound strategy towards commercialization of TrojanDC.

Keywords: cell reprogramming,dendritic cells,transcription factors,immune education,viral delivery,immunotherapy,solid tumors,melanoma,glioblastoma,pancreatic cancer,heterogeneity,immune evasion
metasurface-Integrated Light Detection and Ranging (i-LiDAR)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Systems and communication engineering
Panel description: Electrical, electronic, communication, optical and systems engineering
Countries involved: France
Call: ERC Proof of Concept Grant (ERC-2019-PoC, 2019)
Start date: 2019-12-01
End date: 2021-09-30
Duration (months): 22.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

The “i-LiDAR” PoC project addresses the realisation of high-resolution and high-frame rate imaging systems. Relying on a combination of newly developed planar optical components, known as metasurfaces to achieve large deflection angles, with existing opto-mechanical systems, known for their high-speed light modulations, we will realize new light detection and ranging devices. The proof of concept devices are of great interests for both civil and military applications. Improving the scanning rate by orders of magnitude while preserving a continuous beam steering capabilities, could enable new high-speed applications. Fast imaging i-LiDAR system could be of interest for self-driven cars, giving them sufficiently fast ‘‘visual’’ recognition in order to adjust the driving conditions in real time, for example to drive on highways

Keywords: semiconductor,metamaterials,metasurfaces,antennas,lidar
Unsteady High-Lift Aerodynamics – Unsteady RANS Validation (UHURA)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: Research and Innovation actions
Countries involved: Germany,Spain,Italy,Germany,Sweden,Belgium,France,France,Czechia,Netherlands,Netherlands
Call: Maintaining industrial leadership in aeronautics (H2020-MG-2017-Two-Stages, 2017)
Start date: 2018-09-01
End date: 2022-08-31
Duration (months): 48.0
Total project cost (EUR): 6119233.75
EU funding (EUR): 6119233.75
Participants: 12
Project status: CLOSED

UHURA aims at validating unsteady numerical simulations of the aerodynamics of high-lift systems during deployment and retraction. In detail we perform: - Validation of numerical simulation methods for prediction of the unsteady aerodynamics and dynamic loads during the deployment and retraction phase of high-lift systems. We expect to verify the ability of predicting the unsteady aerodynamics and corresponding loads on the Krueger flap within an accuracy comparable to steady state calculations (less than 1% error in lift, drag and pitching moment). - Quantification of the completely unknown aerodynamic characteristics of a slotted Krueger device during deployment and retraction. We expect to quantify the difference of the actual unsteady loads to the values obtained by state-of-the-art approaches to estimate the critical loads, which are either steady-state predictions or handbook estimations. And, we expect to achieve a system complexity reduction of about 70% by verifying the conceptual feasibility of a central drive architecture for a Krueger flap by properly assessing the handling qualities impact during the deployment. We also expect by this to keep the system weight at or below levels of current state-of-the-art slat devices. Further on, the higher accuracy for load calculations shall reduce the necessary safety margin for the structural sizing due to better knowledge of the actual loads. - Qualification of impact on handling qualities and certification. We expect the Research and Innovation Action to qualify the impact of the unsteady aerodynamic and of the dynamic loads during deployment on the handling qualities and certification issues. The latter also addresses the risk anand mitigation of failure cases.

Keywords: fixed keywords idv,aerodynamics,high lift,unsteady,validation,wind tunnel,laminar wing,krueger flap
Future Leadership in ICT Standards in Europe “ELITE-S” (ELITE-S)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Co-funding of regional, national and international programmes (COFUND)-Fellowship programmes
Action type: Marie Skłodowska-Curie actions
Countries involved: Ireland
Call: Co-funding of regional, national and international programmes (H2020-MSCA-COFUND-2017, 2017)
Start date: 2018-10-01
End date: 2024-09-30
Duration (months): 72.0
Total project cost (EUR): 2265600.0
EU funding (EUR): 1132800.0
Participants: 1
Project status: SIGNED

ICT standards play an essential role in achieving interoperability of new technologies and can bring significant benefits to both industry and consumers. They support the realisation of a European Digital Single Market and allow consumers and businesses the widest choice of products and services across the EU. DCU, host to the ADAPT Centre, is an international hub of scientific expertise related to ICT standards in areas such as data and regulation technologies, data privacy and protection, content analytics, machine learning, preservation, personalisation and interoperability, data and process management. ADAPT will host the ELITE-S Programme which will offer 16 prestigious two-year fellowships for incoming mobility across three calls over the 72 months duration of the programme. Fellowships will be offered in the four core research areas Regulations and Compliance, Content Analytics and Content Preservation, Data and Process Management, Interoperability. ELITE-S applicants will have the freedom to choose their own research topic, their supervisor and their secondment host. The ELITE-S programme will offer excellent quality in the selection of researchers, and high quality training, supervision and training in transferable skills. Specifically: -Provide a state of the art research environment in the area of ICT standardisation related to the programme's core research areas that will stimulate and challenge researchers while developing them as research leaders of the future -Provide fellows with industry-specific training and secondments in priorities sectors including 5G, Internet of Things, Cloud computing, cybersecurity and data technologies -Implement a transparent evaluation and selection process for recruitment -Provide an attractive and supportive working environment for fellows where they are truly integrated into ADAPT and their academic host The ELITE-S programme will train the next generation of leaders in ICT Standards.

Keywords: standardisation,fintech,compliance,interoperability,data management,health informatics,regtech
Understanding collective mechanisms of cell fate regulation using single-cell genomics (AHH-OMICS)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Condensed matter physics
Panel description: Structure, electronic properties, fluids, nanosciences, biological physics
Countries involved: Germany
Call: ERC STARTING GRANTS (ERC-2020-STG, 2020)
Start date: 2021-01-01
End date: 2025-12-31
Duration (months): 60.0
Total project cost (EUR): 1489500.0
EU funding (EUR): 1249292.5
Participants: 2
Project status: SIGNED

Biological systems rely on an influx of energy to build and maintain complex spatio-temporal structures. A striking example of this is the self-organisation of cells into tissues, which relies on an interplay of molecular programs and tissue-level feedback. The mechanistic basis underlying these processes is poorly understood. The recent advent of single-cell sequencing technologies for the first time gives the opportunity to probe these processes with unprecedented molecular resolution in vivo. Biological function, however, relies on collective processes on the cellular scale which emerge from many interactions on the microscopic scale. But what can we learn about such collective processes from detailed empirical information on the molecular scale? Concepts from non-equilibrium statistical physics provide a powerful framework to understand collective processes underlying the self-organisation of cells. In the proposed research endeavour, we will combine the possibilities of novel single-cell technologies with methods from non-equilibrium statistical physics to understand collective processes regulating cellular behaviour. Using this conceptually new approach, we will 1) unveil collective epigenetic processes during differentiation, reprogramming and ageing, 2) determine how the interplay between different layers of regulation leads to the emergence of mesoscopic spatio-temporal structures in vivo, and 3) understand universal fluctuations in gene expression to unveil mechanistic principles of cellular decisions. Our theoretical work will be challenged by single-cell sequencing experiments performed by our collaborators. We will overcome important conceptual limitations in an emerging technology in biology and pioneer the application of methods from non-equilibrium statistical physics to single-cell genomics. At the same time, we take an interdisciplinary approach to tackle questions at the frontier of non-equilibrium physics.

Keywords: single cell genomics,epigenetics,dna methylation,field theory,non equilibrium physics,stem cell biology
Innovative testing of microRNA from liquid biopsies using bistable molecular circuits (DeepMiR)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: France
Call: ERC-Proof of Concept (ERC-2017-PoC, 2017)
Start date: 2017-12-01
End date: 2019-05-31
Duration (months): 18.0
Total project cost (EUR): 149852.0
EU funding (EUR): 149852.0
Participants: 2
Project status: CLOSED

We are designing molecular networks - based on DNA programing- to detect extremely dilute molecular signals and robustly separate them from background noise. This could have relevant applications in the field of molecular diagnostics, in particular in the area of ultra-sensitive testing of nucleic acids from liquid biopsy for example for the detection of circulating microRNA. MicroRNA are difficult targets for standard ultra sensitive techniques such as quantitative PCR, but, because of their presence in the blood stream, they also represent an emerging class of important biomarkers for a wide range of diseases, including cancer. This project will allow us to put together a proof of principle, based of clinically relevant targets and sample, that will clearly demonstrate the benefit of our approach for the molecular diagnostic of microRNA, in terms of sensibility, multiplexing, robustness, modularity and simplicity in sample preparation.

Keywords: microrna,cancer diagnostics,molecular programming,liquid biopsy,circulating biomarkers,solid phase dna amplification,multiplexing,bistable systems,ultrasensitive
Adoptive Gateways for dIverse muLtiple Environments (AGILE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Research and Innovation actions
Countries involved: Austria,Germany,Spain,Spain,Spain,Italy,Italy,Germany,Germany,Spain,Belgium,Belgium,Greece,France,United States,United Kingdom,Denmark,United Kingdom
Call: Internet of Things and Platforms for Connected Smart Objects (H2020-ICT-2015, 2015)
Start date: 2016-01-01
End date: 2018-12-31
Duration (months): 36.0
Total project cost (EUR): 6957550.0
EU funding (EUR): 6857550.0
Participants: 22
Project status: CLOSED

AGILE project aims to create an open, flexible and widely usable IoT solution at disposal of industries (startups, SMEs, tech companies) and individuals (researchers, makers, entrepreneurs) as a framework that consists of: • A modular IoT gateway enabling various types of devices (wearables, home appliances, sensors, actuators, etc.) to be connected with each other and to the Internet; • Data management and device control maximizing security and privacy, at local level and in the cloud, technologies and methodologies to better manage data privacy and ownership in the IoT; • Support of various open and private clouds; • Recommender and visual developer’s interfaces enabling easy creation of applications to manage connected devices and data; • Support of mainstream IoT/M2M protocols, and SDKs from different standardization bodies for device discovery and communication; • Two separate gateway hardware versions: a) the ‘maker’s version, based on the popular RaspberryPi platform for easily prototyping and attracting the current community; b) the ‘industrial’ version for more industrial and production-ready applications; • An ecosystem of IoT applications shareable among users and developers leveraging on existing initiatives by key stakeholders in this domain, like Canonical and Ubuntu Snappy IoT ecosystem. Piloted in relevant open areas (fields and in a port) for field & cattle monitoring through drones, air quality & pollution monitoring and in smart retail, AGILE will be easily adaptable and usable in different contexts serving as an horizontal technology for fast IoT prototyping and engineering in different domains. Following an open hardware/software approach, harnessing the power of IoT developers and entrepreneurs communities, AGILE aims to offer tools to overcome limitations imposed by closed and vertical walled gardens for IoT apps development, offering a fully open platform for integration and adaptation with 3rd parties enabling a new marketplace for IoT apps

Keywords: internet of things,iot gateway,iot app ecosystem
Development of non-antibiotic therapy for the treatment of bovine mastitis (PanaMast)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Biotechnology
Action type: SME instrument
Countries involved: Ireland
Call: SME boosting biotechnology-based industrial processes driving competitiveness and sustainability (H2020-SMEINST-1-2015, 2015)
Start date: 2015-12-01
End date: 2016-04-30
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Bovine Mastitis is a bacterial infection of the cow udder. It is the major problem in the dairy sector, causing losses of approximately €1.5Bn in Europe each year, with each case costing the farmer €285/case. Current treatments use conventional antibiotics. These solutions are not ideal: - they are not always effective - bacteria can gain resistance to the antibiotics - for a period of time during and following treatment (the 'withdrawal period' which can be up to 9.5 days) the milk must be discarded to prevent entry of antibiotic residues into the human food chain Additionally there is a growing pressure for the need for new antibacterial approaches in animal health to lessen the pressures on existing antibiotics for human usage. PanaMast is a novel innovative non-antibiotic antimicrobial technology.We are seeking to develop a novel mastitis treatment based on this technology. It is effective against all bacteria tested in the lab, including antibiotic-resistant strains, such as MRSA. Additionally, bacteria have been unable to gain a resistance to PanaMast. PanaMast is composed of natural products, which have a proven safety and toxicity profile. As such, this non-antibiotic approach aims to be the Worlds first Zero-withdrawal product, allowing farmers to sell milk both during and following treatment, while delivering an effective treatment regimen. In preliminary field trials against mastitis caused by Staph. aureus, we have shown a 70% cure rate, compared to a 5-15% cure rate using conventional treatments. This has a range of advantages over current products, namely: - effective against all bacteria - ability to treat antibiotic-resistant bacteria - no resistance to the product - zero withdrawal period PanaMast therefore has the potential to dramatically improve the way mastitis is treated, resulting in improved health of cows, lessening of economic losses to the farmer and the dairy sector, and provides a needed solution to the growing antibiotic crisis

Keywords: antibiotic replacement,antibiotic resistance,non antibiotic,bovine mastitis,zero milk withdrawal